What is Vogenx?
Headquartered in Durham, North Carolina, Vogenx operates at the intersection of biotechnology and metabolic health. The company is primarily focused on addressing complex physiological dysfunctions, including post-bariatric hypoglycemia, gastroparesis, and obesity. Its core asset, mizagliflozin, represents a first-in-class, oral, small molecule therapeutic designed to modulate glucose absorption and regulate insulin secretion. By targeting the underlying mechanisms of metabolic disorders, Vogenx distinguishes itself as a science-driven innovator capable of delivering high-impact solutions for patients with limited treatment options. The firm's commitment to rigorous clinical validation and novel therapeutic pathways positions it as a key player in the evolving landscape of gastrointestinal and metabolic medicine.
How much funding has Vogenx raised?
Vogenx has raised a total of $81M across 1 funding round:
IPO
$81M
IPO (2026): $81M, investors not publicly disclosed
Key Investors in Vogenx
Undisclosed Investors
What's next for Vogenx?
With the recent influx of capital, Vogenx is poised to advance its lead compound through subsequent clinical trial phases, aiming to solidify its market position as a leader in metabolic therapeutics. The strategic allocation of these funds will likely prioritize the scaling of research and development operations, the optimization of manufacturing processes for its small molecule candidates, and the expansion of its regulatory engagement. As the company moves beyond its current development stage, the focus will shift toward commercialization readiness and the potential for strategic partnerships that could enhance the distribution and accessibility of its innovative treatment modalities. Investors and industry stakeholders will be closely monitoring the firm's progress in navigating the complex regulatory environment and achieving key clinical endpoints.
See full Vogenx company page